Skip to main content

ABBV

Stock
Health Care
Drug Manufacturers - General

Performance overview

ABBV Price
Price Chart

Forward-looking statistics

Beta
0.60
Risk
27.17%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees50K
Market cap$299.2B

Fundamentals

Enterprise value$392.8B
Revenue$57.4B
Revenue per employee—
Profit margin7.31%
Debt to equity4789.60

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$2.35
Dividend per share$6.56
Revenue per share$32.43
Avg trading volume (30 day)$1B
Avg trading volume (10 day)$2B
Put-call ratio—

Macro factor sensitivity

Growth+1.0
Credit+1.1
Liquidity-0.1
Inflation-1.3
Commodities-0.2
Interest Rates-1.0

Valuation

Dividend yield3.47%
PEG Ratio15.60
Price to sales5.83
P/E Ratio15.60
Enterprise Value to Revenue6.85
Price to book235.42

Upcoming events

Next earnings dayApril 25, 2025
Next dividend day—
Ex. dividend dayJuly 15, 2025

News

ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?

AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

Zacks Investment Research (July 11, 2025)
Why Is AbbVie Stock Trading Higher On Thursday?

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI's lead investigational asset, ISBĀ 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.

Benzinga (July 10, 2025)
Final Trades: Abbvie, Boeing, Oracle and Joby Aviation

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television (July 10, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free